Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based oncology treatments.
Y-Mabs Therapeutics Inc. (YMAB)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Caligan Partners David Johnson | 0 | $0 | 0% | |
| 2. | AQR Capital Management Cliff Asness | 0 | $0 | 0% | |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 0 | $0 | 0% | |
| 4. | Point72 Asia (Singapore) Steve Cohen | 0 | $0 | 0% | |
| 5. | Point72 (DIFC) Ltd Steve Cohen | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.85 | 6,455 | $44,231.60 | 4,559,233 | 2023-12-11 | Filing | |
| $6.85 | 6,455 | $44,231.60 | 4,559,233 | 2023-12-11 | Filing | |
| $7.01 | 102,863 | $720,843.33 | 4,552,778 | 2023-12-11 | Filing | |
| $6.99 | 18,503 | $129,378.53 | 4,449,915 | 2023-12-08 | Filing | |
| $6.50 | 6,183 | $40,189.50 | 4,431,412 | 2023-12-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.20 | 3,917 | $20,368.40 | 137,083 | 2025-03-07 | Filing | |
| $5.23 | 10,810 | $56,536.30 | 202,721 | 2025-03-07 | Filing | |
| $12.97 | 30,000 | $389,100.00 | 67,681 | 2024-09-16 | Filing | |
| $13.47 | 65,000 | $875,550.00 | 97,681 | 2024-09-13 | Filing | |
| $15.37 | 50,000 | $768,500.00 | 35,600 | 2024-08-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,061 | $75,487 | 0.01% | |
| 2. | 332 | $2,859 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
11 Best Short-Term Stocks to Invest in
The latter half of the 2025 market is caught between conflicting signals.
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Y-mAbs Therapeutics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Y-mAbs Therapeutics, Inc.'s Earnings Conference Call for the Fourth Quarter and Full Year 2024.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript November 8, 2024Y-mAbs Therapeutics, Inc. reports earnings inline with expectations.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2024 Earnings Call Transcript
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2024 Earnings Call Transcript August 12, 2024Y-mAbs Therapeutics, Inc. misses on earnings expectations.
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Y-mAbs Therapeutics Inc. Earnings Conference Call for the First Quarter of 2024. At this time, all participants are in a listen-only mode.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Y-mAbs Therapeutics Earnings Conference Call for the Fourth Quarter and Full Year of 2023. At this time, all participants are in a listen-only mode.
Hedge Fund Resource Center Billionaire Hedge Funds
